Abstract
The present study was designed to determine whether an association exists between HPA activity and cytokine production in major depression (MD). In 9 patients with MD and 11 control subjects of both sexes, all drug-free, activity of the HPA axis was evaluated by circadian rhythm of plasma cortisol, 24-h free urinary cortisol, an overnight 1 mg dexamethasone suppression test, and an oCRF stimulation test. Spontaneous and LPS-stimulated production of IL-1β, IL-6, and TNFα by peripheral blood mononuclear cells were also determined. We found a significantly elevated spontaneous production of IL-6 in patients with MD (3541.2 ± 726.8 vs 380.4 ± 77.5 pg/mL in controls, p<0.05), while LPS-stimulated production was significantly lower in patients than in control subjects (19,867.7 ± 3649.2 vs 33,142.2 ± 15,47.2 pg/mL, p<0.05). The adrenocorticotropic hormone response to oCRF, evaluated as the area under the curve (AUCACTH) was significantly lower in patients than in control subjects (p=0.02). A positive correlation between AUCACTH and LPS-stimulated IL-6 secretion was observed in patients with MD (r=0.75, p<0.05) but not in controls. These findings suggest that the activation of the inflammatory response described in depression might be associated with long-term hyperactivity of the HPA axis.
Similar content being viewed by others
References
Chrousos, G. P. and Gold, P. W. (1992). JAMA 267, 1244–1252.
Holsboer, F. and Barden, N. (1996). Endocr. Rev. 17, 187–205.
Plotsky, P., Owens, M., and Nemeroff, C. (1998). Psychiatric Clin. North. Am. 21, 293–307.
Musselman, D. and Nemeroff, C. (1995). Endocrinologist 5, 91–96.
Gold, P., Licinio, J., Wong, M. L., and Chrousos, P. (1995). Ann. N.Y. Acad. Sci. 771, 716–729.
Carroll, B. J., Feinberg, M., Greden, J. F., et al. (1981). Arch. Gen. Psychiatry 38, 15–22.
Irwin, M. (1994). Adv. Neuroimmunol. 4, 29–36.
Kathol, R., Jaeckle, R., Lopez, J., and Meller, W. (1989). Br. J. Psychiatry 155, 468–478.
Holsboer, F., von Bardeleben, U., Gerken, A., Stalla, G. K., and Muller, O. A. (1984). N. Engl. J. Med. 311, 1127–1136.
Felten, D. L., Felten, S. Y., Bellinger, D. L., et al. (1987). Immunol. Rev. 100, 225–260.
Arborelius, L., Owens, M. J., Plotsky, P. M., and Nemeroff, C. B. (1999). J. Endocrinol. 160, 1–12.
Cacioppo, J. T., Berntson, G. G., Malarkey, W. B., et al. (1998). Ann. N.Y. Acad. Sci. 840, 664–673.
Schiepers, O. J., Wichers, M. C., and Maes, M. (2005). Prog. Neuropsychopharmacol. Biol. Psychiat. 29, 201–217.
Ader, R., Cohen, N., and Felten, D. (1995). Lancet 345, 99–103.
Haddad, J. J., Saadé, N. E., and Safieh-Garabedian, B. (2002). J. Neuroimmunol. 133, 1–19.
Path, G., Scherbaum, W. A., and Bornstain, S. R. (2000). Eur. J. Clin. Invest. 30, 91–95.
Maes, M., Song, C., Lin, A., et al. (1999). Neuropsychopharmacol. 20, 370–379.
Connor, T. J. and Leonard, B. E. (1998). Life Sci. 62, 583–594.
Maes, M., Meltzer, H. Y., Bosmans, E., et al. (1995). J. Affect. Dissord. 34, 301–309.
Sluzewska, A., Rybakowski, J., Laciak, M., Mackiewicz, A., Sobieska, M., and Wictorowicz, K. (1995). Ann. N.Y. Acad. Sci. 762, 474–482.
American Psychiatric Association. (2000). Diagnostical and statistical manual of mental disorders. 4th ed. APA, Washington DC.
Hamilton, M. (1996). Br. J. Soc. Clin. Psychol. 6, 278–296.
Montgomery, S. A. and Asberg, M. (1979). Br. J. Psychiatry 134, 382–389.
Calfa, G., Kademian, S., Ceschin, D., Vega, G., Rabinovich, G. A., and Volosin, M. (2003). Psychoneuroendocrinology 28, 687–701.
Caroll, B. J., Martin, F. I., and Davies, B. (1968). Br. Med. J. 613, 285–287.
Chrousos, G. P., Schulte, H. M., Oldfield, E. H., Gold, P. W., Cutler, G. B., and Loriaux, L. (1984). N. Engl. J. Med. 310, 622–626.
Arnaldi, G., Angeli, A., Atkinson, A. B., et al. (2003). J. Clin. Endocrinol. Metab. 88, 5593–5602.
Katz, J. R., Taylor, N. F., Goodrick, S., Perry, L., Yudkin, J. S., and Coppack, S. W. (2000). Int. J. Obes. Relat. Metab. Disord. 24, 246–251.
Vgontzas, A. N., Papanicolaou, D. A., Bixler, E. O., Kales, A., Tyson, K., and Chrousos, G. P. (1997). J. Clin. Endocrinol. Metab. 82, 1313–1316.
Straub, R. H., Hense, H. W., Andus, T., Schohnerich, J., Riegger, G. A., and Schunkert, H. (2000). J. Clin. Endocrinol. Metab. 85, 1340–1344.
Maes, M., Calabrese, J., and Meltzer, H. Y. (1994). Prog. Neuropsychopharmacol. Biol. Psychiat. 18, 503–517.
Strickland, P. L., Deakin, J. F., Percival, C., Dixon, J., Gater, R. A., and Goldberg, D. P. (2002). Br. J. Psychiatry 180, 168–173.
Zyah, I. S., Ko, H. C., and Lu, R. B. (1998). Biol. Psychiatry 44, 648–685.
Yanovski, J. A., Yanovski, S. Z., Friedman, T. C., et al. (1996). J. Clin. Endocrinol. Metab. 81, 3307–3311.
Marques-Deak, A. H., Neto, F. L., Dominguez, W. V., et al. (2005). J. Psychiatr. Res. 41, 152–159.
Kagaya, A., Kugaya, A., Takebayashi, M., et al. (2001). Neuropsychobiology 43, 59–62.
Kubera, M., Kenis, G., Bosmans, E., et al. (2000). Pol. J. Pharmacol. 52, 237–241.
Maes, M., Scharpe, S., Meltzer, H. Y., et al. (1993). Psychiatry Res. 49, 11–27.
Seidel, A., Arolt, V., Hunstiger, M., Rink, L., Behnisch, A., and Kirchner, H. (1995). Scand. J. Immunol. 41, 534–538.
Zorrilla, E. P., Luborsky, L., McKay, J. R., et al. (2001). Brain Behav. Immunity 15, 199–226.
Rohleder, N., Wolf, J. M., Piel, M., and Kirschbaum, C. (2003). Psychoneuroendocrinology 28, 261.
Papanicolaou, D. A., Petrides, J. S., Tsigos, C., et al. (1996). Am. J. Physiol. 271, 601–605.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Humphreys, D., Schlesinger, L., Lopez, M. et al. Interleukin-6 production and deregulation of the hypothalamic-pituitary-adrenal axis in patients with major depressive disorders. Endocr 30, 371–376 (2006). https://doi.org/10.1007/s12020-006-0016-1
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12020-006-0016-1